STUDY DESIGN AND METHODS: Data were
analyzed from 20 adult patients with b-thalassemia who were enrolled in a clinical trial of optimizing mobilization strategies for stem cell gene therapy. The aim of this post-hoc analysis was to assess how certain hematological and/or clinical parameters may correlate with low collection efficiency in the presence of adequate numbers of circulating stem cells after pharmacological mobilization and standard leukapheresis procedures. Among 19 patients who achieved optimal mobilization with Plerixafor, four who underwent splenectomy demonstrated disproportionately poor CD341 cell harvests, as determined by their circulating CD341 cell counts after mobilization. All four patients who underwent splenectomy presented at baseline and before first apheresis with lymphocytosis resulting in lymphocyte/neutrophil ratios well above 1 and marked reticulocytosis compared with patients who achieved optimal mobilization/CD341 cell harvest. Such unexpected expansion of specific cell populations disrupted the normal cell layer separation and necessitated modification of the apheresis settings to rescue the harvests.
RESULTS:
CONCLUSIONS: By close examination of certain hematological and/or clinical parameters before leukapheresis, patients who, despite adequate mobilization, are at risk for poor CD341 cell harvests may be identified, and harvest failure can be prevented by adjusting the apheresis settings.
T he collection of mobilized peripheral blood stem cells has been a standard approach for obtaining hematopoietic stem cell grafts in the majority of autologous and allogeneic transplantations. 1 It is well-established that mobilized blood provides several-fold higher numbers of hematopoietic stem cells (HSCs) over bone marrow harvest 2 and that peripheral blood cluster of differentiation 34-positive (CD341) cell counts can reliably predict harvest yields. [3] [4] [5] Stem cell gene therapy applications also pursue the use of peripheral blood because of the high numbers of autologous, genetically modified cells needed for reinfusion into the patient. Although 2 3 10 6 CD341 cells/kg have been considered the minimum threshold for engraftment in autologous transplantation, 6, 7 in specific stem cell gene therapy protocols, like those for b-thalassemia, significantly higher numbers are targeted for an optimal outcome. [8] [9] [10] To define the optimal mobilization approach for adult patients with b-thalassemia, before the implementation of gene therapy, we conducted two mobilization trials investigating four different mobilization modes: granulocyte-colony-stimulating factor (G-CSF) alone, hydroxyurea 1 G-CSF, Plerixafor alone, G-CSF 1 Plerixafor. In these studies, we identified the combination of G-CSF 1 Plerixafor as the optimal mobilization approach and the G-CSF 1 Plerixafor-mobilized cells as the optimal graft source for b-thalassemia gene therapy. [11] [12] [13] Although peripheral blood CD341 cell enumeration still remains the most reliable predictive factor of before apheresis yield, 14 there are rare cases of unexpectedly poor CD341 cell harvests despite successful mobilization. 15, 16 Here, we present four cases among 20 patients with thalassemia who underwent optimal mobilization with Plerixafor but achieved inadequate stem cell harvests due to low collection efficiency. In these patients, disproportionately low yields of CD341 cells with regard to the numbers of circulating CD341 cells were obtained under standard leukapheresis settings or would have been obtained if modification of the leukapheresis settings had not taken place. Limited literature on this matter suggests that red blood cell (RBC) abnormalities could be a factor responsible for this discordance by interfering with the separation of cell layers during leukapheresis.
14,17 Here, we analyzed the factors that, within a homogeneous patient population with overt RBC abnormalities, as in patients with homozygous b-thalassemia, may account for failures to collect circulating CD341 cells using standard apheresis variables. Those patients with thalassemia who are at risk for harvest failure may be identified by certain hematological and/or clinical parameters, and failure to collect CD341 cell numbers proportional to the circulating HSCs can be prevented by adjustment of the apheresis variables.
MATERIALS AND METHODS

Stem cell mobilization
Adult patients with b-thalassemia were enrolled in a Plerixafor-based mobilization clinical trial (EudraCT 2009-014136-37; National Clinical Trial NCT01206075). The trial was approved by the Greek Independent Ethics Committee at the George Papanicolaou Hospital, the Institutional Review Board of the University of Washington, and the Greek National Organization for Medicines. Informed consent was obtained from all enrolled patients according to the Helsinki Declaration. Patients were mobilized with Plerixafor (provided by Sanofi-Genzyme, gratis), and a total of 6 3 10 6 /kg CD341cell yield was determined as a minimum target, in up to two leukapheresis sessions. Plerixafor was administered subcutaneously at 0.24 mg/kg/day on up to 2 consecutive evenings, followed by leukapheresis 10 hours after each dose. Individuals who failed to provide a total of 6 3 10 6 CD341 cells/kg by using Plerixafor alone per two aphereses or those who had failed to mobilize effectively with G-CSF alone in a previous mobilization trial were offered the opportunity to be remobilized with the combination of G-CSF 1 Plerixafor, as previously described.
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Harvest Leukapheresis was performed with a Cobe Spectra apheresis system (Terumo BCT Corporate) using a 33 total blood volume. In the majority of patients, the mononuclear cell collection layer was set according to the manufacturer's instructions. However, in some patients, this interface was reset toward the RBC layer and a higher hematocrit in the colorgram scale, in an effort to rescue the CD341 harvest, as explained. Collection efficiency (CE) of the stem cell harvest was calculated using the following formula: CE 5 total number of harvested CD341cells/(peripheral blood CD341cells/mL 3 apheresis blood volume [L]).
14,15
CD341 enumeration and blood cell counts
Hematopoietic progenitor cells (CD341) in both peripheral blood samples and harvest samples were enumerated by flow cytometry (XL-MCL; Beckman Coulter) using Stem-Kit Reagents (Beckman Coulter) and a singleplatform International Society of Hematotherapy and Graft Engineering protocol, as previously described.
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Complete blood cell counts, automated differentials, and reticulocyte counts were performed on a hematology analyzer (Sysmex XE 5000; TOA Medical Electronics).
Statistics
A descriptive analysis of all continuous variables was performed, including means and standard deviations. Data are expressed as mean 6 standard deviation values. Means of continuous variables were compared using the t test.
RESULTS
Poor harvests in patients with thalassemia who achieve optimal mobilization may be anticipated and prevented by adjustment of apheresis variables
We previously reported the results from two mobilization trials in patients with b-thalassemia that were conducted to optimize the mobilization strategy in this specific population for the purposes of gene therapy. 11, 12 Here, we focus on four patients enrolled in the second trial who were mobilized with Plerixafor and in whom, despite the high numbers of circulating CD341 cells before leukapheresis, adjustments of the apheresis variables were needed to rescue the CD341 cell harvest.
In this trial, 20 patients with b-thalassemia major were enrolled and mobilized with either Plerixafor or G-CSF 1 Plerixafor after previous mobilization failure. Overall, 23 mobilization rounds and 41 apheresis sessions were performed. Here, we refer to optimally mobilized or remobilized patients (with CD341 cells >20/mL) after primary mobilization or remobilization, respectively (n 5 19), excluding from the analyses one patient who did not undergo leukapheresis and three patients who experienced primary mobilization failure.
Patient 10 (P10), a patient who underwent splenectomy and was mobilized with Plerixafor, experienced poor CD341 cell collection in two apheresis sessions (1.7 3 10 6 CD341 cells/kg in total) in the presence of high numbers of circulating CD341 cells (66 and 59 CD341 cells/mL before apheresis sessions 1 and 2, respectively) ( Table 1) . Repeated CD341 cell enumeration, both in the blood sample and in the apheresis product, confirmed the initial measurements. The poor harvest was attributed at that time to a possible, albeit unconfirmed, technical failure. 12 Patient 14 (P14), a second patient who had undergone splenectomy and was mobilized with Plerixafor, again yielded unexpectedly very low CD341cell numbers of cells from the first leukapheresis session (0.75 3 10 6 CD341/kg) despite apparently adequate numbers of blood CD341 cells (36 CD341 cells/mL) ( Table 1 ). This time, it was rather obvious that, in some patients with thalassemia, the formation of separated layers by centrifugation during apheresis is altered, and the mononuclear cell layer moves to a different depth. Thus, the next day, we decided to start the apheresis session for this patient using standard settings, obtain an intermediate graft sample for a CD341 cell count, then modify the apheresis variables to collect from a deeper layer (where the RBCs usually are found), and measure the CD341 cells again in a second intermediate sample. These measurements at a given processed blood volume (5 L and 8.8 L), when extrapolated to the targeted blood volume of processing (15 L), predicted that, by collecting at the standard depth or at a deeper layer, by the end of apheresis, we would harvest 0.6 3 10 6 /kg or 4.6 3 10 6 /kg CD341 cells/kg, respectively. Indeed, after processing 5 L of blood with standard settings, we completed the harvest with the modified instrument settings to collect from a deeper layer, an intervention that rescued both the second and a similarly performed third leukapheresis, yielding 2.73 and 4.33 3 10 6 CD341 cells/kg, in the presence of 61 and 65 circulating CD341 cells/mL, respectively ( Table 1) .
At that time, we went back to the patients' data in an effort to potentially identify a common hematological profile for P10 and P14 that could distinguish them from the rest of the mobilized patients with thalassemia in whom the well-defined correlation between the circulating CD341 cell numbers and apheresis output was confirmed. An initial observation was that a common feature of these two patients, which was not shared by the other previously mobilized thalassemic patients, was a predominance of lymphocytes over neutrophils in the differential counts, both at baseline and before the first apheresis (Table 2) .
P19, a third patient who underwent splenectomy and was mobilized with Plerixafor, presented with higher percentages and absolute numbers of lymphocytes over neutrophils, both at baseline and before the first apheresis. The circulating CD341 cell counts were 76 and 37 per mL before the first and second apheresis, respectively. We decided to harvest CD341 cells upfront from a deeper layer and not to follow the standard settings. Both collections were successful, yielding in total 6.51 3 10 6 CD341 cells/kg (Table 1) . In P20, a fourth patient who underwent splenectomy and was mobilized with Plerixafor, because of borderline relative lymphocytosis before apheresis (Table 2) , we decided to proceed with the standard instrument variables in the first apheresis and, if needed, to modify the settings for the next day apheresis. Even this borderline redistribution of blood leukocytes resulted in a significantly disproportionate yield of CD341 cells with respect to circulating CD341 cells (1.44 3 10 6 CD341 cells/kg and 80 CD341 cells/mL, respectively). After modification to collect from a deeper layer during the second and third leukapheresis sessions, the harvest was rescued, ultimately yielding 9.14 3 10 6 /kg CD341 cells in total (Table 1) . Overall, in three of the four presented patients (P10, P14 and P20, excluding P19 whose collection layer was preemptively modified from the first leukapheresis), the stem cell product from the first apheresis obtained under standard collection settings was disproportionately low with respect to the number of circulating CD341 cells/mL (Table 1) . Collectively, the mean yield of the first leukapheresis in these patients was only 1.02 6 0.38 3 10 6 CD341 cells/kg despite an average of 60.27 6 22.48 circulating CD341 cells/mL (Table 3 ). In contrast, the mean counterpart values for the first apheresis in the remaining patients who also mobilized well (CD341 cells >20/mL), during either primary mobilization or remobilization (n 5 15, excluding one patient who did not proceed to harvest 12 and three who failed primary mobilization), were 5.11 6 3.14 3 10 6 CD341 cells/kg (p 5 0.04) and 71.9 6 54.4 CD341 cells/mL (p 5 nonsignificant), respectively (Table 3) . Indeed, there was a threefold difference in yield in terms of CE between patients who achieved optimal mobilization and harvest and those who achieved optimal mobilization but experienced harvest failure (0.36 6 0.11 vs. 0.1 6 0.01, respectively; p 5 0.001) ( Table 3) . Not unexpectedly, by collecting CD341 cells at a deeper layer (toward the RBC layer), the hemoglobin (Hb) content of the leukapheresis products from these patients was significantly higher than the average Hb concentration in the leukapheresis products obtained from patients in whom leukapheresis was performed under standard operating settings (4.45 6 1.40 vs. 1.12 6 0.75 g/dL; p < 0.00001) ( Table 3) .
Predictive factors of harvest failure in good mobilizers with RBC abnormalities
To define factors that may negatively affect the apheresis output when mobilization per se is successful, we comparatively tested clinical, hematological, and mobilization characteristics of the patients described above with their counterparts among the adequately mobilizing patients, in whom the HSC harvest yield was well correlated with the circulating CD341 cells.
No differences were encountered with regard to age, weight, or ferritin levels at baseline or with regard to platelets, mean cell volume (MCV), Hb levels, or blood CD341 cells either at baseline or before the first apheresis ( Table 3 ). At that time points, however, all four optimally mobilizing patients who either failed or were predicted to fail the first harvest presented predominant relative or/ and absolute lymphocytosis (p 0.0001 and p 0.01, respectively) as well as marked reticulocytosis (p 0.0001) (Tables 2 and 3) . Importantly, the predominance of lymphocytes over neutrophils represented by a lymphocyte to neutrophil count ratio (LNR) greater than 1.0, arose as a highly predictive factor for low CE with the standard apheresis settings, clearly discriminating good mobilizers with low CE from good mobilizers with predictable CE (p 0.000004) (Tables 2 and 3 ). It is also worth mentioning that reticulocytosis only in combination with an LNR greater than 1.0 adversely influenced the HSC harvest (see P2 and P3 vs. splenectomized patients with low CE; Table  2 ).
In addition, all four patients who failed the first harvest had undergone splenectomy, which was correlated with lymphocytosis and reticulocytosis the patients with intact spleen, both at baseline (p 0.01 and 0.03, respectively) and before the first apheresis (p 0.05 and 0.09, respectively) ( Table 4) . Although splenectomy was associated with a higher LNR overall (Table 4) , only those splenectomized patients with baseline and first apheresis LNRs greater than 1.0 in association with reticulocytosis ultimately failed the harvest process (p 0.0007) ( Tables 2  and 5 ).
DISCUSSION
Factors like age, sex, ethnicity, baseline white blood cell count, and differential count have been recognized as having an impact on successful stem cell mobilization by pharmacological agents, both in normal donors and in patients with hematologic malignancies. 20 In addition, several studies have shown that the absolute number of circulating mobilized CD341 cells strongly correlates with the CD341 cell yield of the apheresis product. [3] [4] [5] Nevertheless, the failure of hematopoietic stem cell collection to obtain yields proportional to circulating CD341 cells and the identification of factors that exclusively affect the collection efficiency remain largely unexplored. In the context of gene therapy for b-thalassemia, large numbers of genetically modified HSCs are required for amelioration or correction of the thalassemic phenotype. Mobilized peripheral blood is the preferable source of CD341 cells, because it provides significantly higher numbers than direct bone marrow harvest under a less invasive procedure. In a recent clinical trial from our group, 12 mobilization with G-CSF was shown to be both safe and effective in nonsplenectomized patients with thalassemia major. However in splenectomized patients, hyperleukocytosis emerged as a G-CSF dose-limiting * One patient who was mobilized but did not undergo apheresis and all patients who experienced primary mobilization failure were excluded from the analysis. † The p values were determined using unpaired t tests. ‡ This value refers only to patients who underwent first apheresis using standard settings (n 5
3). § This value refers to apheresis procedures that were performed using the modified device settings. PLT 5 platelets; Neu 5 neutrophils; Lymph 5 lymphocytes; RET 5reticulocytes; PB 5 peripheral blood; LP 5 leukapheresis product; n/s 5 nonsignificant.
factor, ultimately leading to suboptimal or poor CD341 mobilization. In light of these results, in a subsequent trial, we explored the safety and efficacy of Plerixafor, a recently available mobilizing agent used either as a single agent or in combination with G-CSF after primary mobilization failure, in 20 adults with thalassemia major. 13 Here, we performed a post hoc analysis, focusing on the fact that the CD341 cell apheresis yield in some Plerixaformobilized patients was, or would have been, disproportionately poor despite their otherwise successful mobilization. Among the 19 analyzed patients, all of whom achieved optimal mobilization during either primary or secondary mobilization, the stem cell content of the first leukapheresis product in three patients (P10, P14, and P20) was disproportionately low with respect to their circulating CD341 cells; whereas, in another patient (P19), the harvest was rescued by preemptively modifying the device settings. When poor harvest in the absence of mobilization failure was initially encountered (P10), an unconfirmed technical failure was considered possible. Upon re-encountering a poor harvest while adequate circulating CD341 cells were present in P14, we suspected that poor yields in such cases might be related to the apheresis variables. We hypothesized that, in some patients, the mononuclear cell layer containing the CD341 cells may move toward a different depth and, consequently, by using standard settings, the apheresis product is deprived of the precious CD341 cells. However, if apheresis at risk of failure could be recognized in time, then harvests might be rescued by modifying the settings of the apheresis device. Indeed, by adjusting the depth of the collection layer toward the RBC layer, the ultimate yields of leukapheresis in P14, P19, and P20 met expectations based on their preapheresis CD341 counts.
Previously, in the scarce literature addressing the issue of poor stem cell harvest despite adequate mobilization, Wang and coworkers observed that CE in healthy donors who had low MCV was significantly lower than that of donors with normal MCV despite similar mobilization outcomes. 15 In our study, which included a homogeneous patient population with corrected MCV due to regular transfusions, no significant differences in MCV were seen between those who failed or succeeded harvest, as expected.
Here, in a thalassemic patient population who mobilized CD341 cells efficiently, we demonstrate that lymphocytosis associated with reticulocytosis negatively affected stem cell collection by standard apheresis settings. In particular, the combination of an expansion of lymphocytes over neutrophils, represented by an LNR By adjusting the mononuclear cell collection layer toward the RBC layer, the Hb content of the leukapheresis products, as expected, was significantly higher compared with that of the leukapheresis products obtained under standard apheresis settings. Although autologous grafts with higher hematocrits reportedly do not intervene with engraftment, this parameter should be taken into account in collections containing high numbers of damaged and ruptured RBCs if subsequent CD341 cell enrichment is needed (as in thalassemia gene therapy), because the hemolyzed plasma and the numerous dead cells may affect the final purity and recovery of CD341 cells.
Interestingly, another common characteristic of all four patients who required adjustments to rescue the CD341 cell yield, apart from lymphocytosis and reticulocytosis, was splenectomy. Postsplenectomy lymphocytosis, reticulocytosis, and a decrease in RBC deformability have been well evidenced in the literature. 14, 17, [21] [22] [23] In our thalassemic, splenectomized patients, all of these factors may have accounted for the altered cell separation during leukapheresis. In particular, splenectomy, by increasing the probability of lymphocytosis, potentially indirectly increased the chance for an LNR greater than 1.0. Reticulocytosis-albeit linked to the disease background and the interindividual level of anemia or hemolysis-also might have been exacerbated by splenectomy. These postsplenectomy-induced hematological alterations suggest why all individuals with low CE were among those who underwent splenectomy. We identified only one relevant published report of rescuing a harvest by adjusting the apheresis settings to collect in the RBC layer, in a splenectomized patient with b-thalassemia intermedia who had multiple myeloma, underwent G-CSF 1 Plerixafor mobilization for autologous transplantation, and failed the initial stem cell harvest. 16 The authors of that case report hypothesized that the RBC abnormalities and the wide distribution of RBC sizes due to the thalassemic background were responsible for altering cell separation during apheresis.
Although there are not yet data in the literature to support the possibility that the conclusions from our observations could also apply to populations beyond patients with thalassemia, caution should be taken before leukapheresis is initiated in specific hematopoietic stem cell donors with splenectomy and lymphocytosis represented by LNRs greater than 1.0 or/and reticulocytosis, to avoid possible harvest failure when mobilization is optimal. Nevertheless, further studies are needed to solidify the upfront apheresis settings modifications or interim CD341 graft cell counts in other than thalassemic donor populations who exhibit the aforementioned findings.
In conclusion, we present here, within a specific patient population with thalassemia, patients who had poor stem cell yields that were not associated with suboptimal mobilizations; and we highlight the need, in certain patients, for customized stem cell harvests on the basis of specific individual features.
